<img alt="" src="https://secure.soil5hear.com/223550.png" style="display:none;">
Skip to content

3D Tumor Models

Leverage over 1,400 clinically relevant TumorGraft3D models generated from deeply characterized PDX models for advanced ex vivo evaluation of novel cancer therapeutics. The most diverse and clinically relevant bank of 3D tumor models for rapid, reliable, and scalable preclinical oncology research.

 

TumorGraft3D tumor models platform featuring 3D tumor models for organoid screening.

A Biologically-Relevant 3D Platform

Champions offers platforms for ex vivo drug testing in multiclonal 3D organ-like tumor cultures derived from our superior well-characterized patient-derived xenograft (PDX) models.

  • A unique assay with no matrix added and indication-specific proprietary media to allow for TumorGraft3D formation and maintenance 
  • A growing bank of off-the-shelf models across multiple tumor indications that can be used to study the mechanism of action of various therapeutic modalities
  • Available matched TumorGraft3D and TumorGraft® models to enable a smooth transition from ex vivo into in vivo testing

A Versatile 3D Tumor Model Platform to De-Risk In Vivo Studies & Understand Cancer Cell Biology

 

Champions' TumorGraft3D models are derived from our deeply characterized and clinically annotated PDX models. This platform achieves the same turnaround time and throughput of cell line screens, with the added value of leveraging clinically relevant patient-derived models, representative of the heterogeneity of the patient population. All TumorGraft3D models have been tested for their ability to proliferate and compatibility with different assay formats.

Available for large-scale screens or standalone studies, this platform is suitable for a wide range of purposes including rank order of the effect of different test agents across multiple models, investigating tumor cell biology and interaction with the tumor microenvironment, and assessing synergy of therapeutic agents in experimental combinations. Suitable for co-culture with different immune cell types, including Champions' exclusive autologous systems.  

Using sophisticated multi-omics bioinformatic analyses and advanced high-content analysis systems, our scientific team can help you deeply interrogate TumorGraft3D models.

vert-1

TumorGraft3D Platform Endpoints

Cell
imaging
IHC
Flow
Western Blot
Luminex
DNA
NGS
Proteomics
qPCR

 

Download the TumorGraft3D Platform sheet to learn more about Champions' 3D ex vivo platform, assay features and applications, model characterization, and available endpoints.

 

Tab Imges_Medium16

 

Ready to start working with Champions Oncology? 
Frequently Asked Questions
What is the TumorGraft3D platform?

The TumorGraft3D platform is an advanced cancer research tool leveraging Patient-derived Xenograft models to generate a three-dimensional (3D) culture system. Developed by Champions Oncology, this platform allows researchers to study tumor biology and drug responses in a setting that closely mimics the in vivo environment. By maintaining the complex architecture and cell-cell interactions of the original tumor, TumorGraft3D provides more accurate and predictive data for evaluating cancer therapies, bridging the gap between traditional two-dimensional cell cultures and animal models.

Is the TumorGraft3D Platform Ex Vivo or In Vivo?

The TumorGraft3D platform is an ex vivo system. It involves culturing tumor tissues or cells outside of the living organism in a controlled laboratory environment. Unlike in vivo models, where the tumor grows within an animal, TumorGraft3D maintains the tumor’s natural 3D structure and microenvironment in an ex vivo setting, allowing for detailed studies of tumor behavior and drug response in a rapid and cost-effective manner, while still retaining the clinical and biological relevance of the models.

What sets TumorGraft3D models apart from other cell-based platforms?

TumorGraft3D models stand out from other cell-based platforms due to their ability to preserve the native 3D architecture and cellular heterogeneity of the tumor. While traditional 2D cell cultures often fail to replicate the complexities of in vivo tumors, TumorGraft3D models maintain the intricate cell-cell and cell-matrix interactions that are critical for accurate drug testing and biomarker discovery. By only using clinically relevant and low-passage models, this platform provides more biologically relevant data, leading to better predictions of clinical outcomes. Additionally, TumorGraft3D allows for the co-culture of multiple cell types, further enhancing its ability to mimic the tumor microenvironment.

How do I initiate a TumorGraft3D study with Champions?


To initiate a TumorGraft3D study with Champions Oncology, you can follow these steps:

1. Consultation: Contact Champions Oncology to discuss your research objectives and determine how the TumorGraft3D platform can be tailored to meet your specific needs.

2. Proposal Development: Champions will work with you to develop a detailed study proposal, outlining the experimental design, model selection, timelines, and deliverables.

3. Study Agreement: After finalizing the study plan, a formal agreement will be made to outline the terms of the collaboration.

4. Test Agent Shipment: Champions team will work with you on drafting a protocol and provide information on the amount of test agent required.

5. Study Execution: Champions will conduct the study, providing regular updates and detailed data analysis as the research progresses.

6. Data Delivery: Upon completion, Champions scientific team will provide a comprehensive overview of the data generated and help you plan your next experimental steps. You will also receive a comprehensive report with the study’s findings, including i drug efficacy, and potential biomarkers.

Initiating a study with Champions Oncology ensures that you have access to cutting-edge technology, unparalleled models,  and expert guidance throughout your research project.

Get in touch

Fill out the form to get in touch and learn more about our platform and what it can do for you.